Exelixis announces phase 1 trial results of cabozantinib plus nivolumab in advanced genitourinary tumours

Exelixis today announced results from a phase 1 trial of cabozantinib in combination with nivolumab in patients with previously treated genitourinary tumours. The results from the first part of this phase 1 trial will be presented at the European Society for Medical Oncology (ESMO) 2016 Congress, which is being held in Copenhagen on 7-11 October […]

read more

EU approves Cabometyx (cabozantinib) for advanced kidney cancer

The European Medicines Agency (EMA) has approved Cabometyx (cabozantinib) as a second-line treatment option for patients with advanced renal cell carcinoma (RCC) who have previously been treated with vascular endothelial growth factor (VEGF)-targeted therapy. Cabozantinib is manufactured by Exelixis and Ipsen, and was given an accelerated assessment by the EMA. According to the manufacturers, cabozantinib is the first […]

read more

Cabozantinib and lenvatinib recommended for approval by the EMA

Cabozantinib (Cabometyx, Ipsen Pharma) and lenvatinib (Kisplyx, Eisai Europe Ltd) have been recommended for approval by the European Medicines Agency (EMA). This will soon give kidney cancer patients in Europe, who are not responding to treatment, two new options to try. The EMA is the European Union agency responsible for the protection of public and animal […]

read more

Cabozantinib extends survival in advanced kidney cancer compared to axitinib

Results from the phase III METEOR clinical trial, which compares cabozantinib (Cabometxy) with everolimus (Afinitor) in patients with advanced renal cell carcinoma (RCC) who have had prior anti-angiogenic therapy, were presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago last week. The results showed almost a 30% increase in overall survival (OS) compared […]

read more

Cabozantinib improves progression-free survival in renal cell carcinoma

Results from the phase II CABOSUN trial, released this week, have shown that cabozantinib (Cabometyx) significantly improved progression-free survival (PFS) compared with sunitinib (Sutent) in advanced renal cell carcinoma (RCC) patients who had not received any previous drug treatment. The safety profile for cabozantinib was similar to that previously reported in advanced RCC. Cabozantinib, a […]

read more

Cabozantinib receives FDA approval for kidney cancer

Exelixis has announced that the US Food and Drug Administration (FDA) has approved CABOMETYX™ (cabozantinib) tablets for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy. CABOMETYX, which was granted Fast Track and Breakthrough Therapy designations by the FDA, is the first therapy to demonstrate clinically meaningful improvement […]

read more
Showing 61 to 66 of 66 results